Open AccessShort-Term Effect of Zidovudine on Plasma and Genital Human Immunodeficiency Virus Type 1 and Viral Turnover in These Compartments
Author(s) -
Dorothy MboriNgacha,
Barbra A. Richardson,
Julie Overbaugh,
Dana Panteleeff,
Ruth Nduati,
Matt Steele,
Grace JohnStewart
Publication year - 2003
Publication title -
journal of virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.617
H-Index - 292
eISSN - 1070-6321
pISSN - 0022-538X
DOI - 10.1128/jvi.77.13.7702-7705.2003
Subject(s) - zidovudine , biology , virology , sex organ , cervix , human immunodeficiency virus (hiv) , viral load , sida , vagina , lentivirus , immunology , viral disease , cancer , genetics
The effect of zidovudine on plasma and genital human immunodeficiency virus type 1 (HIV-1) was determined in 42 antiretroviral-naive HIV-1-seropositive women in Nairobi. After 7 days of zidovudine treatment, HIV-1 RNA levels decreased by 0.5 to 1.1 log(10) in plasma and genital secretions. HIV-1 RNA half-life following zidovudine treatment was 4.7, 1.3, and 0.9 days in plasma, cervix, and vagina, respectively, and significantly shorter in genital secretions than in plasma (P < 0.001). Defining the short-term effect of zidovudine on plasma and genital HIV-1 is important for improving perinatal HIV-1 interventions.